Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis

Lancet. 1994 Oct 15;344(8929):1052-4. doi: 10.1016/s0140-6736(94)91710-8.


The role of iron supplementation in treating the anaemia of systemic-onset juvenile chronic arthritis is not clear. Eight affected children with severe persistent anaemia unresponsive to oral iron therapy were treated with intravenous iron saccharate. From a median post-oral-iron value of 8.0 g/dL (range 6.5-9.5), haemoglobin rose to 11.0 g/dL (10.1-12.1) (p = 0.01). The concentration of serum transferrin receptor, an indicator of iron deficiency, before intravenous therapy correlated with the increase in haemoglobin (r = 0.88, p < 0.01). Intravenous iron saccharate could be an effective treatment for chronic anaemia in this condition, especially with iron deficiency not responsive to oral iron.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anemia, Iron-Deficiency / drug therapy*
  • Anemia, Iron-Deficiency / etiology
  • Arthritis, Juvenile / complications*
  • Child
  • Child, Preschool
  • Hemoglobins / analysis
  • Humans
  • Infant
  • Injections, Intravenous
  • Iron / administration & dosage*
  • Receptors, Transferrin / analysis


  • Hemoglobins
  • Receptors, Transferrin
  • Iron